The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Open accessAbstract
Key Points: The posttreatment end point progression of FL within 24 months (POD24) is strongly associated with OS. A pretreatment clinicogenetic risk model (m7-FLIPI) predicts POD24 and OS and identifies the smallest subgroup with highest unmet need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Cited by
Chimeric antigen receptor T-cell therapies for lymphoma
Brudno, J. N., & Kochenderfer, J. N. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 516
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00889-8 · Cited by 337
Bachy, E., Seymour, J. F., Feugier, P., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Catalano, J. V., Brice, P., Lemonnier, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01073 · Cited by 290
Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López-Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 278
Metadata
- Authors
- Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., Barr, P. M., Friedberg, J. W., Ansell, S., Sehn, L. H., Connors, J. M., Gascoyne, R. D., Hiddemann, W., Unterhalt, M., Weinstock, D. M., & Weigert, O.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-08-25
- Volume
- 128
- Issue
- 8
- Pages
- 1112-1120
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2464635942
- Cited by
- 233
- References
- 2
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. https://app.cochat.ai/papers/10.1182/blood-2016-05-717355
- The paper
- Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., Barr, P. M., Friedberg, J. W., Ansell, S., Sehn, L. H., Connors, J. M., Gascoyne, R. D., Hiddemann, W., Unterhalt, M., Weinstock, D. M., & Weigert, O. (2016). Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. https://doi.org/10.1182/blood-2016-05-717355
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.